Your browser doesn't support javascript.
Icotinib as initial treatment in lung adenocarcinoma patients with brain metastases.
Thorac Cancer ; 7(4): 437-41, 2016 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-27385986
ABSTRACT

BACKGROUND:

To evaluate the antitumor activity and toxicity of icotinib as initial treatment in lung adenocarcinoma patients with brain metastases.

METHODS:

Twenty-one patients with histologically or pathologically documented brain metastatic lung cancer were administered icotinib as initial treatment from 2011 to 2015 at the Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Chemotherapy response was assessed by Response Evaluation Criteria in Solid Tumors and toxicity was evaluated according to National Cancer Institute-Common Toxicity Criteria. Icotinib was administered three times per day at a dose of 125mg.

RESULTS:

The median overall and progression-free survival rates were 15.2 (1.2-31.5 months, 95% confidence interval [CI] 6.6-23.7 months) and 8.9 months (0.6-30.5 months, 95% CI 3.4-14.3 months), respectively. The overall response and disease control rates were 61.9% and 90.5%, respectively. Icotinib was well tolerated, and no grade 3/4 adverse events were observed. The most common grade 1/2 adverse events included acneiform eruptions (38.1%), diarrhea (19.0%), and stomatitis (9.5%).

CONCLUSION:

Icotinib is effective and well tolerated as initial treatment in lung adenocarcinoma patients with brain metastases.

Similares

MEDLINE

...
LILACS

LIS

Texto completo: Disponível Coleções: Bases de dados internacionais Base de dados: MEDLINE Idioma: Inglês Revista: Thorac Cancer Ano de publicação: 2016 Tipo de documento: Artigo